%20(2).jpeg "Roundup: Holmusk partners with American mental healthcare provider, MyHealthcare introduces latest HIMS and more briefs")
Holmusk signs the use of technology with a US-based mental health provider.
US-based Metrocare Services has signed an agreement with Holmusk, a Singapore behavioral health technology provider, use its real-world data platform to improve mental health care.
Metrocare is a leading provider of mental health and developmental disability services in Texas.
The agreement is for the use of NeuroBlu, a data platform featuring a 20+ year-old clinical dataset derived from more than half a million patients worldwide. It synthesizes this data using proprietary analytics, natural language processing, and disease predictive models designed for behavioral health.
By offering data, analytics and digital solutions, Holmusk’s platform helps improve patient engagement, supports disease self-management and captures patient-reported outcomes.
The usage agreement will provide Metrocare with access to data analytics to improve care delivery while improving NeuroBlu by applying real-world evidence to drive insights for behavioral health care.
“As the largest provider of behavioral health care in North Texas, predictive analytics allows us to be even more proactive in responding to the needs of our community and prioritizing patient care,” said Metrocare CEO , Dr. John W. Burruss.
“It will be a privilege to collaborate with Metrocare to increase our understanding of mental health conditions and, more importantly, to improve the care provided to patients in Dallas and around the world,” said the medical director of Holmusk, Scott Kollins.
Indian health tech startup unveils hospital information management system
MyHealthcare, an Indian health technology startup, has launched its task-based healthcare information management system for hospitals and healthcare providers.
The MyHealthcare Enterprise Application (MHEA) uses process automation and artificial intelligence to deliver relevant information and help staff complete tasks from a single screen. Its ecosystem supports acquisition improvements through intelligent storage and improves the patient experience through automation of the discharge process. Built on an open source stack, the platform is also cost-effective, the company claims.
MyHealthcare has designed its latest app to drive process and operational efficiencies across a provider’s network. CIO Aneesh Nair said they are offering their system to secondary, tertiary and emergency care services.
In addition to helping providers complete their digitization process, MHEA is said to reduce staff training time by around 80%, according to Divya Laroyia, product manager at the company.
MHEA also comes integrated through a network of third-party administrators and health insurance companies.
Genesis MedTech buys manufacturer of valve replacement devices
Singaporean medical device company Genesis MedTech has acquired JC Medical, a Chinese manufacturer of transcatheter valve replacement devices for the minimally invasive treatment of structural heart disease.
JC Medical’s J-Valve is a minimally invasive transcatheter aortic valve replacement (TAVR) device. It consists of a transapical TAVR already in use in China and a transfemoral TAVR that has received premarket approval from the US Food and Drug Administration.
According to the company, the device is one of only two products worldwide that has been approved for patients with aortic regurgitation and stenosis. J-Valve can serve different types of patients, including those with low coronary ostial height and small sinuses. Its design is also touted to reduce stent migration, ensuring safety and clinical efficacy.
Genesis MedTech is venturing into the structural heart franchise by adding JCM TAVR to your wallet. “By doing this, we hope to better support cardiac surgeons and cardiologists in their fight against structural heart disease,” said President and CEO Warren Wang.
Although structural heart disease affects more than 2% of people worldwide today, its prevalence is increasing as the world’s population ages, the company noted. In China, 25 million people are living with the condition, while more than 5 million people are diagnosed annually in the US. As TAVR implementations have overtaken surgical aortic valve replacement in the US, this trend could continue in China by 2025, says Genesis MedTech.
In the meantime, Zhang Ji, founder and president of JCM, will continue in his role, in addition to his appointment as CTO of the latest Genesis MedTech franchise.
Excelra and X-Chem collaborate to accelerate drug discovery
India-based life sciences analytics firm Excelra and X-Chem, a US AI drug discovery platform, have partnered to combine their technologies to accelerate drug discovery.
Excelra’s GOSTAR is an application that provides a comprehensive view of more than 8 million small molecules, capturing the latest information on chemical structures and their biological properties. Its proprietary data is meticulously selected with its own QMS-ISO certified process.
X-Chem’s RosalindAI platform is used to create AI models for chemical design and optimization. When the platform was trained on GOSTAR data, it produced AI models that are “twice as good” as models trained on other datasets.
“This new synergistic partnership between Excelra’s GOSTAR and X-Chem’s RosalindAI will enable unique and powerful tools to predict small molecules, chemical, biological and physical properties, accelerating the time and resource-intensive steps of drug discovery from successful identification to preclinical screening of candidates,” the companies said in a press release.
